RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma

NCT ID: NCT01545635

Last Updated: 2016-03-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2016-02-29

Brief Summary

Severe traumatized patients (ISS > 15) admitted to emergency department (ED) University Hospital Innsbruck with obvious bleeding and/or who are at risk for significant hemorrhage will be screened by rotational thrombelastometry (ROTEM) assays during ED treatment and subsequent surgical/radiological interventions for having coagulopathy (T0). If a patient meets the inclusion criteria (T1) and is recruited for the study, a first study related blood sample (40mL) will be drawn, and data collected. Subsequently, 100 patients will be randomized to receive Fibrinogen concentrate and/or Prothrombin complex concentrate and/or FXIII concentrate for reversal of coagulopathy, while the other 100 patients will receive fresh frozen plasma (FFP),respectively.

Treatment failure will be registered if bleeding persists and ROTEM parameters do not improve after two times dosages of study drug. In these cases haemostatic rescue therapy will be administered. CFC (fibrinogen concentrate and/or PCC, and/or FXIII concentrate) will be administered to patients randomized to receive FFP and FFP will be administered to patients of the CFC group.

In cases unresponsive to comprehensive treatment or normal ROTEM combined with diffuse bleeding, other haemostatic medications can be administered (e.g rFVIIa, DDAVP, VWF/FVIII concentrate) as judged by the anesthetist in charge. The need and type of any rescue therapy will be documented and a ROTEM will be performed thereafter.

At admission to ICU (T0 ICU), 24h (T24 ICU) and 48h(T48 ICU) thereafter further study related blood samples are drawn (40mL each).

The indications for transfusion of red blood cells or platelets, administration of antifibrinolytics, treatment of acidosis, hypothermia, hypocalcemia and volume replacement are similar for both groups and treatment is performed according to clinical routine.

Besides coagulation management during ED treatment until 24h on ICU, patient's care is not influenced by the study and follows clinical routine.

Conditions

Major Trauma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Coagulation factor concentrates

Group Type: ACTIVE_COMPARATOR

Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate

Intervention Type: DRUG

Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min

Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min

FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.

Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min

Fresh Frozen Plasma

Group Type: ACTIVE_COMPARATOR

Fresh Frozen Plasma blood type 0, A, B and AB

Intervention Type: DRUG

Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min

Interventions

Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate

Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min

Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min

FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.

Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min

Intervention Type: DRUG

Fresh Frozen Plasma blood type 0, A, B and AB

Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 \<7mm and/or ExTEM CT\>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female subjects =/> 18 years and =/< 80 years

2. Major trauma (ISS > 15)

3. Clinical signs of ongoing bleeding or patients who are at risk for significant haemorrhage assessed and judged by the ED team in charge of patient

4. Presence of coagulopathy defined by ROTEM assays as follows,

• Patients with concomitant decreased fibrinogen polymerisation (ROTEM® FibTEM A10 of < 7 mm after 10 min)
• Patients with concomitant decreased coagulation factor levels (ROTEM® ExTEM CT of > 90 sec)

Exclusion Criteria

1. Lethal injury

2. CPR on the scene,

3. Isolated brain injury, burn injury

4. Avalanche injury

5. Administration of FFP or coagulation factor concentrates before ED admission

6. Delayed (> 6hours after trauma) admittance to ED

7. Known use of oral anticoagulants, or platelet aggregation inhibitors within 5 days before injury

8. Known history of severe allergic reaction to plasma products

9. Known history of congenital hemostasis disturbance, IgA or Protein C deficiency

10. Patients with a history of thromboembolic events or heparin induced thrombocytopenia (HIT) type 2 within the last year

11. Patients with a body weight < 45kg and > 150kg

12. Patients that are known to be pregnant

13. Jehova's Witness

14. Known participation in another clinical trial

15. Patient with known refusal of a participation in this clinical trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical University Innsbruck

OTHER

Sponsor Role: lead

Responsible Party

Univ.-Doz. Dr. Petra Innerhofer

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Medical University Innsbruck / Department for Anesthesia and Intensive Care Medicine

Innsbruck, Tyrol, Austria

Countries

Austria

References

Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, Gruber G, Schmid S, Friesenecker B, Lorenz IH, Strohle M, Rastner V, Trubsbach S, Raab H, Treml B, Wally D, Treichl B, Mayr A, Kranewitter C, Oswald E. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017 Jun;4(6):e258-e271. doi: 10.1016/S2352-3026(17)30077-7. Epub 2017 Apr 28.

Reference Type: DERIVED

PMID: 28457980 (View on PubMed)

Other Identifiers

RETIC

Identifier Type: -

Identifier Source: org_study_id